Table 1 Comparisons of clinical characteristics between low SIRI and high SIRI groups in the original, matched and weighted cohorts.
Features | Original cohort | Matched cohort | Weighted cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
Low SIRI | High SIRI | P-value | Low SIRI | High SIRI | P-value | Low SIRI | High SIRI | P-value | |
N | 192 | 106 | 83 | 83 | 85.5 | 86.3 | |||
Age, years | 57.2 (12.4) | 55.3 (13.7) | 0.226 | 5796 (11.3) | 56.5 (13.4) | 0.462 | 56.8 (12.5) | 56.7 (13.4) | 0.953 |
Gender, male, n (%) | 105 (54.7) | 67 (63.2) | 0.193 | 46 (55.4) | 50 (60.2) | 0.637 | 52.5 (61.3) | 53.8 (62.3) | 0.880 |
BMI (kg/m2) | 22.5 (2.9) | 22.6 (2.9) | 0.842 | 22.3 (2.4) | 22.5 (3.0) | 0.570 | 22.5 (2.8) | 22.6 (3.0) | 0.899 |
Primary site, n (%) | 0.404 | 0.874 | 0.989 | ||||||
Left colon | 103 (53.6) | 53 (50.0) | 43 (51.8) | 45 (54.2) | 45.7 (53.4) | 45.8 (53.0) | |||
Right colon | 48 (25.0) | 34 (32.1) | 25 (30.1) | 22 (26.5) | 23.7 (27.8) | 24.7 (28.6) | |||
Rectum | 41 (21.4) | 19 (17.9) | 15 (18.1) | 16 (19.3) | 16.1 (18.8) | 15.9 (28.4) | |||
Histological grade, n (%) | 0.010 | 0.871 | 0.975 | ||||||
Well differentiated | 38 (19.8) | 34 (32.1) | 26 (31.3) | 24 (28.9) | 25.7 (30.1) | 26.4 (30.6) | |||
Moderately | 146 (76.0) | 63 (59.4) | 52 (62.7) | 55 (66.3) | 54.4 (63.6) | 55.0 (63.7) | |||
Poorly differentiated | 8 (4.2) | 9 (8.5) | 5 (6.0) | 4 (4.8) | 5.5 (6.4) | 4.9 (5.7) | |||
Tumor size, n (%) | 0.005 | 0.636 | 0.961 | ||||||
<2 cm | 12 (6.2) | 3 (2.8) | 4 (4.8) | 3 (3.6) | 3.2 (3.8) | 2.7 (3.1) | |||
2–5 cm | 113 (58.9) | 46 (43.4) | 39 (47.0) | 34 (41.0) | 37.9 (44.3) | 37.9 (43.9) | |||
≥5 cm | 67 (34.9) | 57 (53.8) | 40 (48.2) | 46 (55.4) | 44.4 (52.0) | 45.7 (52.9) | |||
T stage, n (%) | 0.527 | 0.493 | 0.959 | ||||||
T1/2 | 14 (7.3) | 6 (5.7) | 6 (7.2) | 3 (2.6) | 4.8 (5.6) | 4.7 (9.5) | |||
T3/4 | 178 (92.7) | 100 (94.3) | 77 (92.8) | 80 (96.4) | 80.7 (94.4) | 81.6 (94.5) | |||
N stage, n (%) | 0.033 | 0.868 | 0.984 | ||||||
N1 | 110 (57.3) | 44 (421.5) | 38 (45.8) | 41 (49.4) | 40.8 (47.8) | 42.2 (48.9) | |||
N2 | 45 (23.4) | 35 (33.0) | 28 (33.7) | 25 (30.1) | 26.4 (30.9) | 25.8 (29.9) | |||
N3 | 37 (19.3) | 27 (25.5) | 17 (20.5) | 17 (20.5) | 18.3 (21.4) | 18.3 (21.1) | |||
M stage, n (%) | 0.005 | 1.000 | 0.966 | ||||||
M0 | 169 (88.0) | 79 (74.5) | 68 (71.9) | 68 (71.9) | 70.6 (82.6) | 71.1 (82.4) | |||
M1 | 23 (12.0) | 27 (25.5) | 15 (18.1) | 15 (18.1) | 14.9 (17.4) | 15.2 (17.6) | |||
TNM stage, n (%) | 0.017 | 0.634 | 0.881 | ||||||
Stage I/II | 96 (50.0) | 37 (34.9) | 31 (37.3) | 35 (42.2) | 34.7 (40.7) | 35.9 (41.6) | |||
Stage III/IV | 96 (50.0) | 69 (65.1) | 52 (62.7) | 48 (57.8) | 50.8 (59.3) | 50.4 (58.4) | |||
Chemotherapy, n (%) | 0.758 | 0.532 | 0.899 | ||||||
No | 81 (42.2) | 42 (39.6) | 39 (47.0) | 34 (41.0) | 36.4 (42.6) | 36 (41.8) | |||
Yes | 111 (57.8) | 64 (60.4) | 44 (53.0) | 49 (59.0) | 49.1 (57.4) | 50.3 (58.2) | |||
Post radiotherapy, n (%) | 0.352 | 0.212 | 0.932 | ||||||
No | 176 (91.7) | 101 (95.3) | 82 (98.8) | 78 (94.0) | 81.8 (95.6) | 82.3 (95.4) | |||
Yes | 16 (8.3) | 5 (4.7) | 1 (1.2) | 5 (6.0) | 3.7 (4.4) | 4.0 (4.6) | |||
Laboratory results | |||||||||
WBC, ×109/L | 5.4 (2.0) | 8.1 (3.1) | <0.001 | 5.3 (1.4) | 8.1 (3.2) | <0.001 | 5.5 (1.5) | 8.1 (2.3) | <0.001 |
HGB, g/dL | 111.1 (26.0) | 109.6 (24.2) | 0.621 | 113.1 (23.0) | 107.9 (25.3) | 0.174 | 112.7 (24.9) | 108.0 (24.7) | 0.150 |
PLT, ×109/L | 234.5 (81.1) | 276.4 (90.8) | <0.001 | 237.0 (97.5) | 276.0 (91.5) | 0.009 | 237.2 (89.0) | 277.7 (92.6) | 0.001 |
Albumin, g/L | 39.6 (4.5) | 38.0 (5.5) | 0.006 | 39.2 (4.5) | 38.0 (5.6) | 0.120 | 39.3 (4.7) | 37.7 (5.5) | 0.017 |
TBIL, μmol/L | 10.9 (3.5) | 10.9 (3.9) | 0.991 | 10.6 (3.1) | 10.7 (3.1) | 0.890 | 10.9 (5.2) | 10.7 (5.0) | 0.800 |
Creatinine, umol/L | 71.5 (16.8) | 73.4 (20.6) | 0.399 | 71.7 (14.4) | 73.7 (20.2) | 0.463 | 72.1 (14.8) | 72.8 (20.2) | 0.769 |
BUN, mmol/L | 4.9 (1.5) | 5.0 (1.9) | 0.530 | 4.8 (1.5) | 5.1 (2.1) | 0.340 | 5.0 (1.5) | 5.1 (1.9) | 0.629 |
LDH, U/L | 179.9 (46.9) | 218.4 (81.8) | <0.001 | 178.5 (37.4) | 209.5 (96.1) | 0.013 | 180.5 (52.4) | 213.9 (90.8) | 0.011 |
CEA, μg/L | 25.4 (12.2) | 224.5 (47.1) | 0.062 | 23.4 (6.3) | 233.2 (55.0) | 0.251 | 29.3 (7.6) | 241.8 (58.6) | 0.224 |
CA19-9, U/mL | 94.6 (59.6) | 174.4 (93.2) | 0.051 | 87.4 (54.4) | 141.5 (78.4) | 0.332 | 121.8 (62.0) | 168.8 (72.0) | 0.411 |
CA125, U/mL | 21.0 (9.6) | 38.0 (18.2) | 0.129 | 25.8 (10.3) | 30.1 (11.1) | 0.629 | 19.9 (9.7) | 30.0 (11.2) | 0.040 |
CA72-4, U/mL | 8.0 (6.5) | 15.4 (15.4) | 0.017 | 9.8 (7.0) | 10.1 (6.5) | 0.921 | 9.3 (6.0) | 12.9 (11.9) | 0.298 |
OS months | 19.2 (9.1) | 18.3 (9.8) | 0.479 | 18.2 (9.0) | 19.9 (10.7) | 0.291 | 18.7 (9.3) | 19.0 (10.9) | 0.824 |
DFS months | 18.8 (8.3) | 16.8 (8.1) | 0.120 | 17.7 (9.0) | 18.7 (10.2) | 0.565 | 18.1 (9.2) | 18.0 (9.3) | 0.907 |
Death, n (%) | 18 (9.4) | 31 (29.2) | <0.001 | 12 (14.5) | 24 (28.9) | 0.024 | 11.7 (13.7) | 23.3 (26.9) | 0.018 |
Recurrence, n (%) | 26 (13.5) | 43 (40.6) | <0.001 | 14 (16.9) | 33 (39.8) | 0.003 | 16.2 (18.9) | 31.0 (35.9) | 0.006 |
